Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04439578
- Locations
- 🇨🇳
Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04435158
- Locations
- 🇨🇳
2nd Xiangya Hospital , Chinese Academy of Medical Sciences, Changsha, Hunan, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT04425876
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Phase 3
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT04426955
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
Phase 1
Completed
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04428086
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: SHR6390 tablet
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04423601
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 179
- Registration Number
- NCT04417972
- Locations
- 🇨🇳
Peking University Third Hospital, Peking, Beijing, China
A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04414150
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function
Phase 1
- Conditions
- Subjects With Impaired Renal Function and Healthy Subjects
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04414852
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Phase 3
Terminated
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 185
- Registration Number
- NCT04409223
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath